Abstracts tagged "Arthritis"

Abstract Number: 2326 • 2014 ACR/ARHP Annual Meeting
Investigation of Parameters Used to Test Quadriceps Muscle Power Using Isokinetic Dynamometer in Arthritis
Maria Beatriz Catelani¹, Samannaaz S. Khoja², Gustavo J. Almeida² and Sara R. Piva¹, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA
Background/Purpose Muscle power (MP) plays an important role in daily activities that require force generated at fast speeds such as climbing stairs. MP is decreased…
Abstract Number: 1087 • 2014 ACR/ARHP Annual Meeting
The Prevalence of Knee Arthritis and Associated Self-Reported Limitation of Activity in Chinese Populations
Xu Tang Sr., Ke TAO, Qiang LIU, Xu Wu, Zheng Ming Cao and Jian Hao Lin, Arthritis Institute, People’s Hospital, Peking University, Beijing, China
Background/Purpose To estimate the prevalence of knee arthritis and assess the association between knee arthritis and self-reported limitation of activity in Chinese Populations. Methods Populations:…
Abstract Number: 2302 • 2014 ACR/ARHP Annual Meeting
Classification of Juvenile Spondyloarthropathies According to ASAS Criteria
Marìa M. Katsicas¹ and Ricardo A. G. Russo², ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose The juvenile spondyloarthropathies (JSpA) are a group of related seronegative rheumatic diseases characterized by involvement of the axial , peripheral large joints and entheses.…
Abstract Number: 994 • 2014 ACR/ARHP Annual Meeting
IL-7 Modulates B Cell Immunoglobulin Isotype Production and Increases B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Synovial Fibroblasts from Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients
Georg Pongratz¹, Stephan Kuhn², Madlen Melzer², Torsten Lowin² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Interleukin(IL)-7 is increased in synovial fluid from rheumatoid arthritis (RA) patients as compared to osteoarthritis (OA) patients and has been attributed a proinflammatory role,…
Abstract Number: 2198 • 2014 ACR/ARHP Annual Meeting
The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing?
Zsolt Kulcsar¹, Clinton Morgan², Peter Kaufman³, Jonathan Jones⁴ and William Rigby⁵, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Hematology/Oncology, Dartmouth Hitchcock Medical Center, lebanon, NH, ⁴Rheumatology Clinic, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ⁵Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH
Background/Purpose: Aromatase Inhibitor (AI) therapy is the most effective hormonal treatment in post-menopausal estrogen receptor (ER) positive breast cancer. These patients may be seen by…
Abstract Number: 927 • 2014 ACR/ARHP Annual Meeting
Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice – a New Potential Role for TRPA1 in Gout
Lauri J Moilanen, Mari Hämäläinen, Lauri Lehtimäki, Riina Nieminen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland
Background/Purpose: In the gout, monosodium urate (MSU) crystals deposit intra-articularly and cause painful arthritis. In the present study we tested the hypothesis that Transient Receptor…
Abstract Number: 2172 • 2014 ACR/ARHP Annual Meeting
PTPN22 Promotes TLR-Induced Amelioration of Arthritis
David Ewart¹, Erik J. Peterson¹ and Yaya Wang², ¹University of Minnesota, Minneapolis, MN, ²Center for Immunology, University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) synovial fluid exhibits high levels of type 1 interferons (IFN). Type 1 IFN may exert potent anti-inflammatory effects, since a TLR3…
Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
René Cordtz¹, Lene Mellemkjær², Bente Glintborg¹, Merete Lund Hetland³ and Lene Dreyer¹, ¹Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ³DANBIO Registry and Department of Rheumatology., Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…
Abstract Number: 2187 • 2014 ACR/ARHP Annual Meeting
Revisiting RS3PE after Twenty Five Years: A Systematic Review of 250 Cases
Paras Karmacharya¹, Anthony Donato², Madan Aryal³, Sushil Ghimire⁴, Ranjan Pathak³, Kalpana Shah⁵, Pragya Shrestha⁶, Ananta Subedi⁷, Smith Giri⁸, Leena Jalota³, Dilli Poudel⁴ and David George⁹, ¹Internal MEdicine, Reading Health System, West Reading, PA, ²Internal medicine, Reading Health System, Reading, PA, ³Internal medicine, Reading Health System, West Reading, PA, ⁴Reading Health System, West Reading, PA, ⁵Internal medicine, Mymensingh Medical College, Mymensingh, Bangladesh, ⁶Internal medicine, Nanjing Medical University, Nanjing, China, ⁷Suite 511 Russell Morgan Build, Good Samaritan Hospital, Baltimore, MD, ⁸Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁹Internal Medicine, Reading Health System, Reading, PA
Background/Purpose Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome is a rare inflammatory arthritis, first described by McCarty et al in 1985 characterised by…
Abstract Number: 830 • 2014 ACR/ARHP Annual Meeting
Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.¹, Anna Klukovits², Keith Barnes³, Chitkala Satyanarayana⁴, Chris Cheeseman⁵ and John Piwinski¹, ¹Relburn-Metabolomics, Inc., Westfield, NJ, ²SOLVO Biotechnology, Budapest, Hungary, ³AMRI, Albany, NY, ⁴AMRI, Singapore, Singapore, ⁵University of Alberta, Alberta, AB, Canada
Background/Purpose: A prototype anticancer drug (RLBN1001) induced marked hypouricemia in studies of > 350 human subjects. Preliminary exploration suggested dual effects on uric acid (UA)…
Abstract Number: 2162 • 2014 ACR/ARHP Annual Meeting
Immunological Abnormalities in Adult Patients with Parvovirus B19 Infection : A study of 23 Cases
Edouard Pertuiset, Farid Kemiche, Mehdi Yahia and Isabelle Cerf-Payrastre, Rheumatology, Centre Hospitalier René Dubos, Pontoise, France
Background/Purpose In adults, parvovirus B19 infection can induce joint symptoms and cutaneous manifestations which are known to be transient most of the time. It has…
Abstract Number: 346 • 2014 ACR/ARHP Annual Meeting
Treatment of Collagen Induced Artritis with Human Embrionic Stem Cell-Derived Multipotent Mesenchymal Stromal Cells (hESC-MSC)
Gabriel Criado¹, María J. Pérez-Lorenzo¹, María Galindo², Jose L. Pablos², Pablo Menéndez³ and Elena Gonzalo-Gil⁴, ¹Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Josep Carreras Leukemia Research Insitute, Barcelona, Spain, ⁴Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose Inhibition of TGFβ signaling in human Embryonic Stem Cells (hESC) generates mesenchymal stromal cells (hESC-MSC) with osteogenic, adipogenic and chondrogenic potential. These cells have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.